Falcigo 60mg Injection contains Artesunate, a potent antimalarial agent used primarily for the treatment of severe malaria caused by Plasmodium falciparum. Artesunate belongs to the artemisinin class of drugs, which act rapidly to reduce the parasite load in the bloodstream by generating reactive oxygen species that damage the parasite’s proteins and membranes. This injection is typically administered intravenously or intramuscularly in hospital settings, ensuring quick absorption and prompt therapeutic effects, especially in critically ill patients. Falcigo 60mg Injection is indicated for severe malaria cases where oral medication is not feasible due to vomiting or unconsciousness. The drug’s rapid action helps prevent complications such as cerebral malaria, organ failure, and death. Dosage and duration of treatment depend on the patient’s weight and clinical response, and it is often followed by a complete course of oral antimalarials to ensure parasite clearance. Common side effects may include mild allergic reactions, dizziness, or gastrointestinal disturbances, but serious adverse effects are rare when used appropriately. Caution is advised in patients with known hypersensitivity to artesunate or related compounds. Falcigo 60mg Injection is a critical component in the management of severe malaria, contributing significantly to reducing mortality rates worldwide.